HeartBeam (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

Questions around this news

What can the HeartBeam System do?
The release describes the HeartBeam System as a portable, cable-free ECG system that can synthesize a 12-lead ECG for assessing arrhythmias. It says the system’s ECG view can help clinicians evaluate rhythm abnormalities and identify changes that may need further investigation. The release does not describe specific monitoring schedules or clinical outcomes.
What is a synthesized 12-lead ECG?
A 12-lead ECG presents the heart’s electrical activity from multiple perspectives, helping clinicians assess its rhythm and other features. A synthesized ECG uses recorded information and computational methods to generate a view resembling a standard 12-lead ECG. How it is produced and validated depends on the particular system.
What does FDA-cleared mean for a medical device?
FDA clearance generally means the U.S. Food and Drug Administration has determined that a medical device can be marketed for specified uses under a regulatory pathway that compares it with an appropriate existing device. Clearance is distinct from FDA approval, and it does not mean a device is suitable for every patient or use.
How does cardiac monitoring outside a healthcare facility differ from an ECG in a clinic?
The release contrasts routine 12-lead ECG use in clinical settings, which it says involves bulky equipment, adhesive electrodes and trained personnel, with its goal of making cardiac monitoring accessible beyond medical facilities. It describes the system as portable and cable-free, but does not provide details about how or how often patients use it.

Advances in digital health, cloud computing and data analytics are making it possible to move beyond episodic monitoring toward a more comprehensive understanding of cardiovascular health.
HeartBeam’s proprietary HeartBeam System reflects the company’s mission to make cardiac monitoring accessible beyond the walls of a medical facility.
The synthesized 12-lead ECG view provided by the system can help clinicians evaluate rhythm abnormalities and identify rhythm changes that may warrant additional investigation.

Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of a healthcare facility. As healthcare increasingly emphasizes earlier intervention and more personalized care, HeartBeam (NASDAQ: BEAT) is developing technologies designed to transform where and how cardiac data are captured, analyzed and shared, including its proprietary, FDA-cleared HeartBeam System, the first portable, cable-free ECG system capable of synthesizing a 12-lead ECG for assessment of arrhythmias.

For decades, cardiac monitoring has relied on the standard 12-lead ECG but its use has been confined to clinical settings, requiring bulky equipment, adhesive electrodes and trained personnel to administer. This means the most clinically meaningful cardiac data is only available in a doctor’s office or hospital and…

At a glance

Company: HeartBeam
Ticker: NASDAQ: BEAT
Announcement: Product

Key figures

ECG leads synthesized: 12-lead

Products and programs

HeartBeam System

SEC filings

Earlier from HeartBeam

Back to News Center

HeartBeam (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

Questions around this news

What can the HeartBeam System do?

What is a synthesized 12-lead ECG?

What does FDA-cleared mean for a medical device?

How does cardiac monitoring outside a healthcare facility differ from an ECG in a clinic?

At a glance

Key figures

Products and programs

SEC filings

Earlier from HeartBeam